辛伐他汀联合环磷腺苷治疗冠心病慢性心力衰竭疗效观察

Observation on the efficacy of simvastatin combined with cyclic adenosine phosphate in the treatment of chronic heart failure in patients with coronary heart disease

目的：探讨辛伐他汀联合环磷腺苷治疗冠心病慢性心力衰竭的临床疗效。方法选取2013年7月至2015年6月接受治疗的冠心病慢性心力衰竭患者100例，分为对照组（50例）和观察组（50例）。对照组患者采用常规治疗，观察组患者在常规治疗的基础上采用辛伐他汀联合环磷腺苷治疗。结果治疗后，观察组总有效率为81．0％，对照组为70．0％，两组总有效率差异无统计学意义（χ2＝3．0606， P ＞0．05）；治疗后两组患者 LVESD、LVEDD 较治疗前明显下降，LVEF 明显升高（P ＜0．05）；治疗后观察组LVESD（36．1±3．9）mm、LVEDD（45±10．4）mm，明显低于对照组的 LVESD（41．3±4．2）mm、LVEDD（58．0±10．6）mm，而 LVEF（55．0±9．2）％，明显高于对照组（38．0±7．5）％（t ＝6．1237、7．1149、6．3257，均 P ＜0．05）。结论辛伐他汀联合环磷腺苷用于治疗冠心病慢性心力衰竭具有较好的治疗效果，能够有效改善患者心功能，提高患者预后生活质量。

Objective To explore the clinical effect of simvastatin combined with cyclic adenosine phosphate in the treatment of chronic heart failure in patients with coronary heart disease.Methods 1 00 patients with chronic heart failure who received treatment during July 201 3 and June 201 5 were randomly divided into control group （50 cases）and observation group （50 cases）.The control group was treated with conventional therapy,and the obser-vation group was treated with simvastatin combined with cyclic adenosine.Results The total effective rate of the observation group was 81 .0%,which of the control group was 70.0%,the total effective rate of the two groups had no obvious difference（χ2 =3.060 6,P 〉0.05）.The LVEDD,LVESD in the two groups significantly decreased compared with before treatment,LVEF significantly increased after treatment（P 〈0.05）.After treatment,the LVESD,LVEDD of observation group were （36.1 ±3.9）mm,（45.0 ±1 0.4）mm,which were significantly lower than （41 .3 ±4.2） mm,（58.0 ±1 0.6）mm of the control group.The LVEF of observation group was （55.0 ±9.2）%,which was signifi-cantly higher than （38.0 ±7.5）% of the control group （t =6.1 23 7,7.1 1 4 9,6.325 7,all P 〈0.05）.Conclusion Simvastatin combined with adenosine cyclophosphate for the treatment of chronic heart failure of coronary heart disease has good treatment effect,can effectively improve the prognosis of patients with cardiac function to improve patients quality of life.